News

Tympanogen awarded $3.23 million grant from National Institutes of Health to accelerate clinical study

Tympanogen, a medical device company based in the Biotech Park of Richmond, VA, was awarded a $3.23 million Small Business Innovation Research (SBIR) grant from the National Institute on Deafness and Other Communication Disorders (NIDCD). This Commercialization Readiness Pilot (CRP) Program grant, a continuation of a prior Direct-to-Phase II grant, will support the pivotal clinical study for the company’s nonsurgical eardrum repair device. This device, called Perf-Fix™ Otologic Gel Patch, is intended to replace surgical eardrum repair with a clinic visit. It will be for both children and adults suffering from chronic eardrum perforations – a significant issue that follows middle ear infection.

“This SBIR CRP Program award enables us to provide qualifying patients with a faster, safer alternative to current surgical options for eardrum repair through a clinical study. We are honored that the NIDCD has continued to support the commercialization of Perf-Fix so we can reach patients more quickly,” said Dr. Elaine Horn-Ranney, Co-Founder and Chief Executive Officer of Tympanogen and the Principal Investigator for the grant.

“Perf-Fix has been developed alongside otolaryngologists continuously since its inception, and it is exciting to be able to use it in practice for this study,” said Dr. Barry Strasnick, Chair of the Department of Otolaryngology at Eastern Virginia Medical School, Clinical Advisor to Tympanogen, and Study Investigator. “With this clinical study, Perf-Fix could become the leader in noninvasive eardrum repair because it avoids the risk and cost of surgery for this highly prevalent condition.”

The clinical study for Perf-Fix has been approved by an Institutional Review Board and will be conducted at multiple sites across the United States. Enrollment for the study is anticipated to begin in the fourth quarter of 2023.

Recent News

07/01/2025

ISOThrive Announces Promising Phase 2 Interim Data for Novel Heartburn Treatment and Appoints Pharma Veteran Mike Walther as Chief Strategy Officer

ISOThrive Inc., a clinical-stage biopharmaceutical company, announced interim results from a Phase 2 study of its lead candidate, ISOT-101, for treatment of Non-Erosive Reflux Disease (NERD). The data showed positive trends in addressing heartburn frequency and symptom severity among proton pump inhibitor (PPI) partial-responders (PR), a patient population with major unmet medical need. These positive

07/01/2025

Gary Lowenthal Joins Focused Ultrasound Foundation’s Council

The Focused Ultrasound Foundation is pleased to welcome Gary Lowenthal to its Council, a dedicated group of goodwill ambassadors who work closely with the Board of Directors and staff to provide advice and assist with raising funds and building awareness. Mr. Lowenthal is a retired educator, entrepreneur, and executive with a career spanning education, international service,

06/25/2025

Liquet Medical Closes Oversubscribed Seed Round to Launch Pilot Study Evaluating Real-Time Hemodynamic Monitoring

Liquet Medical, a clinical-stage medical device company developing the Versus™ Catheter — a first-of-its-kind dual-tipped catheter system cleared by the FDA for controlled and selective infusion of fluids into the pulmonary vasculature and hemodynamic monitoring — announced the successful and oversubscribed close of its Seed funding round, which officially closed in May 2025. The capital